Blueblood Ventures FY26 Results: Net profit rises 4.5x to ₹3.26 lakh
- Net profit after tax rose 4.5x YoY to ₹3.26 lakh in FY26
- Total revenue grew 38% to ₹110.64 lakh, driven by operational sales
- Other expenses surged to ₹97.03 lakh, mainly due to business promotion costs
- Trading remains suspended since 2022; delisting waiver application pending
*this image is generated using AI for illustrative purposes only.
Blueblood Ventures Limited reported a 4.5x increase in net profit for FY26, driven by higher revenue and improved other income. The company’s shares remain suspended on the BSE following regulatory non-compliance issues dating back to 2022.
The SME-listed entity posted a total revenue of ₹110.64 lakh for the financial year ended March 31, 2026, up from ₹80.08 lakh in FY25. Net profit after tax rose significantly to ₹3.26 lakh, compared to ₹0.59 lakh in the previous year. This improvement was supported by a reduction in employee benefits expense and finance costs, despite a sharp increase in other expenses.
Financial Performance
Revenue from operations grew by nearly 58% to ₹79.18 lakh, while other income remained stable at ₹31.46 lakh. The company recorded a profit before tax of ₹4.27 lakh, against ₹0.81 lakh in FY25. Total expenditure stood at ₹106.36 lakh, up from ₹79.27 lakh.
| Metric | FY26 (₹ lakh) | FY25 (₹ lakh) | Change |
|---|---|---|---|
| Revenue from Operations | 79.18 | 50.02 | +58.3% |
| Other Income | 31.46 | 30.06 | +4.7% |
| Total Revenue | 110.64 | 80.08 | +38.2% |
| Total Expenditure | 106.36 | 79.27 | +34.0% |
| Profit Before Tax | 4.27 | 0.81 | +427.2% |
| Net Profit After Tax | 3.26 | 0.59 | +452.5% |
What the Numbers Show
Other income constituted 28.4% of total revenue in FY26, indicating a continued reliance on non-operating streams such as interest income (₹21.46 lakh) and miscellaneous income (₹9.99 lakh). While revenue from operations expanded, "other expenses" surged to ₹97.03 lakh from ₹10.72 lakh in FY25, largely driven by ₹93 lakh in business promotion costs. This expense growth nearly offset the gains from operational revenue expansion, highlighting a shift in cost structure rather than pure operational efficiency.
Balance Sheet and Regulatory Status
As of March 31, 2026, the company held long-term borrowings of ₹9,400 lakh, primarily comprising zero-coupon optionally convertible debentures. Short-term borrowings decreased to ₹50.91 lakh from ₹292.93 lakh. Trade receivables fell to ₹1,398.69 lakh from ₹2,127.41 lakh, while long-term loans and advances increased to ₹6,346.28 lakh.
Trading in Blueblood Ventures’ securities has been suspended since November 21, 2022, due to non-compliance with SEBI regulations. The company received a show-cause notice in December 2025 regarding potential compulsory delisting and has submitted a waiver application to the BSE, which remains pending. No dividend was declared for FY26.
What specific regulatory milestones must Blueblood Ventures achieve to resolve the pending waiver application and potentially lift the BSE trading suspension?
How sustainable is the 4.5x profit growth given that ₹93 lakh of the expenditure surge was attributed to one-off business promotion costs rather than operational efficiency?
What is the likely impact on the company's liquidity and debt servicing capability if the zero-coupon optionally convertible debentures are converted or called for repayment in the near term?
19
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
